New drug SPN-817 aims to tame Hard-to-Control seizures
NCT ID NCT06798896
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether SPN-817 can reduce seizure frequency in adults with focal onset seizures that don't respond well to current medications. About 216 participants will receive either SPN-817 or a placebo, and researchers will track seizure changes over 14 weeks. The goal is to see if SPN-817 is safe and effective for this condition.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SPN-817
- What this could lead to
- If successful, this could provide a new treatment option for adults with hard-to-control focal seizures, potentially reducing seizure frequency.
- What could go wrong
- This is an early Phase 2 trial with only 216 participants, so results may not confirm effectiveness or safety. Side effects are possible, and the drug may not work better than placebo.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FOCAL ONSET SEIZURES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Medsol Clinical Research Center
RECRUITINGPort Charlotte, Florida, 33952, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.